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Vasculitis is a heterogeneous group of disorders characterized by the presence of necrotic inflammatory phenomena and destruction
of blood vessels. Vasculitis is classified as primary (idiopathic) or secondary to infections, connective tissue diseases and drugs but
can also be considered as a paraneoplastic phenomenon. Evidence shows that the increasing use of biological agents results in a
growing number of reports of autoimmune diseases induced by these therapies. An inflammatory articular chronic disease such
as rheumatoid arthritis may be complicated by extra-articular manifestations, such as cutaneous or systemic vasculitis. Herewith,
we describe the case of a great vessels arteritis in a patient affected by rheumatoid arthritis in therapy with an anti-TNF agent
(etanercept).
1. Introduction
Inhibitors of tumor necrosis factor (TNF) are an effective
therapy for rheumatic and systemic autoimmune diseases
but the increasing use of these agents has caused secondary
autoimmune conditions, such as vasculitis. Moreover, we
know that rheumatoid arthritis (RA) is an inflammatory
chronic articular disease that can be complicated by extra-
articularmanifestations, especially in cases of aggressive, long
standing, seropositive RA. In our report, we describe the case
of a great vessels arteritis in a patient with RA in therapy with
etanercept.
2. Case Presentation
A 65-year-old Italian female was formerly diagnosed with
seropositive (rheumatoid factor (RF) and anticitrullinated
protein antibodies (anti-CCP)) RA with etanercept treat-
ment since 2007. The inflammatory disease was in clini-
cal, biohumoral, and ultrasonographic remission for two
years at least. The patient had previously undergone ther-
apy with DMARDs (hydroxychloroquine, leflunomide, and
methotrexate) and oral corticosteroids without significant
benefits. Her medical history was otherwise relevant just
for RA. She was admitted for a few days to the Emergency
Room for the onset of headache and persistent abdominal
pain with nausea. After admission to the Emergency Depart-
ment, no signs of systemic inflammation nor any focus of
infections were identified. During the hospitalization, an
abdominal ultrasonography and a gastroscopy were per-
formed to exclude acute gastritis or colelitiasis, and detected
hepatic steatosis and acute gastritis with hiatal hernia. Labo-
ratory exams showed elevated markers of inflammation (C-
reactive protein (CRP) 28,35mg/dL; D-dimer 6530 ng/mL).
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A thoracoabdominal angio-CT was performed suspecting
arterial thrombosis and revealed a parietal thrombosis of
the common hepatic artery with focal dissection, a focal
thrombosis of superior mesenteric artery, an infarction of
the lower pole of the right kidney and the upper third
of the spleen. The autoimmunity markers as well as the
cancer markers were negative. Therefore, an anticoagulant
therapy was started. Subsequently, suspecting vasculitis as
a feasible paraneoplastic manifestation, a positron emission
tomography (PET) was necessary and revealed a flogistic
involvement of the entire aorta (Figure 1). In conclusion,
the diagnostic hypothesis was either RA-related-aortitis or
a side effect to etanercept. The anti-TNF therapy was
stopped and glucocorticoid therapy was started at doses of
1mg/kg/daily in association with one dose of intravenous
pulse cyclophosphamide (750mg). This latter treatment was
repeated after two and three months. Laboratory tests and
clinical examinations showed a favorable outcome just one
month later, also confirmed by a negative PET scan control
performed after three months (Figure 2). The patient is still
followed in our unit and continues treatment with daily
oral cyclophosphamide (100mg), daily prednisone (25mg),
and ongoing anticoagulant therapy. Markers of inflammation
have normalized and the patient reported an improvement of
her clinical status.
3. Discussion
The primary systemic vasculitides are heterogeneous, multi-
system disorders characterized by inflammation and necro-
sis of small and medium blood vessels. Their aetiology
is unknown. Vasculitic syndromes are considered in the
differential diagnosis of patients with multisystem illness or
pyrexia of unknown origin. However, there are a number
of specific conditions that can mimic vasculitis, including
infections and noninfectious inflammatory diseases, malig-
nancy, and drugs. Vasculitis occurs commonly in the context
of other autoimmune connective tissue diseases such as
systemic lupus erythematosus and RA.
In our patient, infective agents, as possible triggers of a
vasculitic process, have also been excluded. In literature, few
cases of vasculitides due to infections are reported indeed;
generally, these are forms of cutaneous vasculitis. Moreover,
the manifestation of infective endocarditis often resembles
vasculitis. The possibility of underlying infectious diseases
in patients presenting symptoms and signs of vasculitis and
vice versa should always be considered before diagnosing
vasculitis [1]. Considering large vessels disease, it is known
that infectious aortitis is a rare but life-threatening disorder
mostly associated with abdominal aortic aneurysms; they
may result from bacteremia and embolization of infectious
material, which cause superinfection of a diseased and
roughened atherosclerotic surface [2].
We have considered the differential diagnosis with a
paraneoplastic vasculitis in our clinical case too, but this
was not confirmed by laboratory and instrumental inves-
tigations. The association between cancer and vasculitis is
uncommon and difficult to establish. Overall, paraneoplastic
vasculitides are estimated to represent about 2–5% of all
vasculitides.The only cancer-specific association with a given
vasculitis is that of hairy cell leukemia and polyarteritis
nodosa that typically affect medium-sized muscular arteries,
also described in a variety of other malignancies. However,
few cases of large-vessel vasculitis primarily occurring in
the setting of myelodysplastic syndromes and myeloprolif-
erative disorders are described in the published literature
[3, 4].
As previously mentioned, we have observed the relation-
ship between vasculitis and anti-TNF therapy in the literature.
So TNF has been successfully targeted in the management of
adult inflammatory arthritis to produce remission of disease
and improvement in radiological progression [5]. Although
these agents have been studied during the past and have
demonstrated acceptable profiles of tolerability and safety,
there are a growing number of reports of adverse events such
as infection, an increased risk of solid tumors and lymphoma,
cardiovascular disease, demyelinating disorders, and autoim-
mune processes ranging from asymptomatic immunological
alterations to life-threatening systemic autoimmune disease.
In 2006, the Study Group on Autoimmune Diseases (GEAS)
of the Spanish Society of Internal Medicine created a multi-
center study on the use of biological agents in adult patients
with systemic autoimmune disease. This study also aimed to
evaluate the occurrence of autoimmune disorders secondary
to the use of biological agents, such as vasculitis, sys-
temic lupus erythematosus/lupus-like syndrome, psoriasis,
interstitial lung disease, antiphospholipid syndrome, ocular
autoimmune diseases, sarcoidosis, autoimmune hepatitis,
and inflammatory myopathies. In this study, 118 patients
(the majority with RA) developed vasculitis after starting
anti-TNF-agents. In 51% of the patients, the biological agent
was etanercept, in 43% infliximab and in 4% adalimumab.
Vasculitis occurred as cutaneous lesions in 86% of cases;
only 2 patients presented involvement of large arteries.
The mechanisms that might participate in the induction of
this latter in patients receiving TNF blockers are not fully
understood. It has been suggested that anti-TNF-𝛼/TNF-𝛼
immune complexes could be deposited in small capillaries,
where they activate complement and thereby trigger a type
III hypersensitivity reaction [6]. The etiologic role of anti-
TNF could be justified by several factors: the occurrence of
vasculitis was associated with the initiation of therapy and
resolved in more cases after discontinuation of biological
agents; the cutaneous lesions started at the injection site
(particularly in patients in therapy with etanercept) [7–9].
The genetic predisposition is an important factor to consider
in these cases [10, 11].
Recently there have been reports of large vessels vasculitis
(Takayasu’s arteritis (TA)) in patients receiving anti-TNF-
therapy [12]. In another report, Mariani et al. described
the first case of TA in RA patients under anti-TNF-therapy
(adalimumab) [13]. The development of a vasculitis in a
patient with an inflammatory disease during biologic therapy
may be due to an imbalance in immune homeostasis.
Vascular involvement is a fundamental part of the patho-
genesis of RA. The vascular lesions of the blood vessels in
RA are mostly asymptomatic but occasionally may cause
severe manifestations. Approximately 2%–5% of RA patients
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Figure 1: Positron emission tomography: increased uptake by the thoracic and abdominal aorta and aortic arch, indicating great vessels
arteritis.
develop rheumatoid vasculitis (RV), an extra-articular man-
ifestation affecting small and medium-size arteries.
The concept of RV was first developed when vasculi-
tis with important clinical manifestations occurred in RA
patients. RV was so considered when clinical expressions
of vasculitis were unexplained by other conditions such
as diabetes, atherosclerosis, infections, drugs, malignan-
cies, and other vasculitides [14]. Although the pathogenetic
mechanisms underlying systemic vasculitis are still unclear,
immune complexes probably play a great role. This is
supported by the strong association of systemic vasculitis
with higher titers of RF. Deposition of immune complexes
can induce flogistic cascade with the release of cytokines,
including TNF-𝛼, IL-1, and IL-6. Flogistic processes of RA
involve capillaries, arterioles, and venules just from the
early stages, with progressive degenerative changes of the
endothelium and the possible formation of thrombi, with
resulting localized ischemia. The vessels most commonly
involved are those of the skin and vasa nervorum of the
peripheral nerves, whereas the central nervous system, eyes,
heart, lungs, kidneys, and gastrointestinal system are less
frequently affected [15]. The typical patient with RV has a
long severe history of rheumatic disease. RA that causes
aortitis is mostly a severe, seropositive, and nodular disease,
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Figure 2: Positron emission tomography 3 months after the initiation of cyclophosphamide and steroids therapy.
associated with extra-articular vasculitic manifestations [16]
and the strongest association with the development of RV is
an increased titer of RF. A possible approach to the diagnosis
of RV is a set of criteria proposed by Scott and Bacon in
1984 [17]. We also observed the onset of large-vessel arteritis
(TA specifically) in patients with a history of RA. Although
the relationship between RA and TA is unknown it can be
assumed that a vascular nonspecific activation of a chronic
inflammatory disorder in the presence of a predisposing
genetic background can lead to the development of this
disease [18, 19].
As mentioned, our patient was considered in clini-
cal, biohumoral, and ultrasonographic remission, without
extra-articularmanifestations.Therefore, a strong correlation
with RV is not clear indeed. In the medical literature, 213
cases of TNF-induced vasculitis have been reported: most of
the patients had RA. Although the spectrum of vasculitis was
broad, there was a predominance of cutaneous involvement
but an important finding was the presence of systemic
vasculitis in an equally large number of patients.
It can be challenging to determine causes of vasculi-
tis associated with anti-TNF-therapy; the resolution of
vasculitis after drug therapy discontinuation and adju-
vant treatment is often helpful in supporting the etiologic
role of anti-TNF-therapy in the development of vasculitis
[9].
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4. Conclusion
In our report, the patient developed a condition of vasculitis
during treatment with anti-TNF. At the time of admission we
evaluated the possible causes of her clinical manifestations.
We excluded the main infectious and paraneoplastic forms,
through specific instrumental and laboratory investigations.
In literature, some authors have reported cases of vasculitis
during treatment with biological drugs, which gradually
improved after high doses of steroids and immunosuppres-
sive therapy and the discontinuation of anti-TNF.We can also
assume that the aortitis could result from the complication of
the chronic, inflammatory articular disease.
Our report demonstrates the development of a great ves-
sel vasculitis in a RA patient under treatment with etanercept.
Large cohort studies of patients under biological therapy
could help us to understand the relationship between vascular
disease and drugs and to find patients that could develop
systemic vasculitis. Moreover, all patients with inflammatory
arthritis must be carefully monitored for the risk of devel-
opment of an occlusive arterial involvement, with or without
anti-TNF-therapy.
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